Graffinity lines up IPO after raising €31m venture capital

Graffinity, the German biotech company, has raised €31m ($27.4m) of venture capital in its last round of financing ahead of its initial public offering, which is scheduled for 2003.

Merlin Biosciences, a venture capitalist specialising in the biotechnology sector, was the biggest single investor in this financing round. Graffinity brought in three other new investors - GIMV, Oxford Bioscience Partners and The Dow Chemical Company.

WSJ Logo
How Trump Got His ‘Big, Beautiful Bill’ Across the Finish LineExternal link

How Trump Got His ‘Big, Beautiful Bill’ Across the Finish Line